Syndax Pharmaceuticals SNDX Ratios & Valuation
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Profitability | |||||
| Operating margin | -158.2%+1,276pp | -1,434.4%— | —— | —— | |
| Net margin | -165.4%+1,181pp | -1,346.1%— | —— | —— | |
| Returns | |||||
| Return on equity | -161.8%-86.1pp | -75.7%-34.7pp | -41%-6.9pp | -34.1%-41.6pp | |
| Return on invested capital | -50.3%+13.5pp | -63.8%+6.5pp | -70.3%-18.1pp | -52.2%-68.3pp | |
| Efficiency | |||||
| Asset turnover | 0.3×+0.2× | 0×— | 0×— | 0×-0.4× | |
| Liquidity | |||||
| Current ratio | 4.4×-1.4× | 5.8×-4.2× | 10×-6.9× | 16.9×-4.8× | |
| Leverage | |||||
| Debt-to-equity | 5.4×+3.1× | 2.3×+2.3× | 0×0.0× | 0×0.0× | |
| Per Share | |||||
| Book value per share | $0.75-77.8% | $3.37-57.3% | $7.88+2.4% | $7.69+1.0% | |
| Valuation | |||||
| Market capitalization | $1.83B+61.8% | $1.13B-28.0% | $1.57B-9.6% | $1.73B+46.7% | |
| Price / sales | 10.6×-37.1× | 47.7×— | —— | —— | |
| Price / book | 28.3×+24.3× | 3.9×+1.1× | 2.8×-0.9× | 3.7×+0.8× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Syndax Pharmaceuticals's ratios come from?
- Every ratio is computed from Syndax Pharmaceuticals's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
